204 related articles for article (PubMed ID: 29650275)
1. Metformin for non-small cell lung cancer patients: Opportunities and pitfalls.
Levy A; Doyen J
Crit Rev Oncol Hematol; 2018 May; 125():41-47. PubMed ID: 29650275
[TBL] [Abstract][Full Text] [Related]
2. Impact of metformin use on survival outcomes in non-small cell lung cancer treated with platinum.
Wen-Xiu X; Xiao-Wei Z; Hai-Ying D; Ying-Hui T; Si-Si K; Xiao-Fang Z; Huang P
Medicine (Baltimore); 2018 Dec; 97(51):e13652. PubMed ID: 30572481
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of metformin for non-small cell lung cancer patients with diabetes.
Xu T; Li D; He Y; Zhang F; Qiao M; Chen Y
World J Surg Oncol; 2018 Mar; 16(1):60. PubMed ID: 29558957
[TBL] [Abstract][Full Text] [Related]
4. Metformin as a repurposed therapy in advanced non-small cell lung cancer (NSCLC): results of a phase II trial.
Parikh AB; Kozuch P; Rohs N; Becker DJ; Levy BP
Invest New Drugs; 2017 Dec; 35(6):813-819. PubMed ID: 28936567
[TBL] [Abstract][Full Text] [Related]
5. Improved progression free survival for patients with diabetes and locally advanced non-small cell lung cancer (NSCLC) using metformin during concurrent chemoradiotherapy.
Wink KC; Belderbos JS; Dieleman EM; Rossi M; Rasch CR; Damhuis RA; Houben RM; Troost EG
Radiother Oncol; 2016 Mar; 118(3):453-9. PubMed ID: 26861738
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes.
Chen H; Yao W; Chu Q; Han R; Wang Y; Sun J; Wang D; Wang Y; Cao M; He Y
Cancer Lett; 2015 Dec; 369(1):97-102. PubMed ID: 26341687
[TBL] [Abstract][Full Text] [Related]
7. Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes.
Tan BX; Yao WX; Ge J; Peng XC; Du XB; Zhang R; Yao B; Xie K; Li LH; Dong H; Gao F; Zhao F; Hou JM; Su JM; Liu JY
Cancer; 2011 Nov; 117(22):5103-11. PubMed ID: 21523768
[TBL] [Abstract][Full Text] [Related]
8. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
Hasegawa Y; Ando M; Maemondo M; Yamamoto S; Isa S; Saka H; Kubo A; Kawaguchi T; Takada M; Rosell R; Kurata T; Ou SH
Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199
[TBL] [Abstract][Full Text] [Related]
9. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Murphy M; Stordal B
Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis.
Byeon S; Ham JS; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Med Oncol; 2016 Aug; 33(8):97. PubMed ID: 27447711
[TBL] [Abstract][Full Text] [Related]
11. Metformin in lung cancer: rationale for a combination therapy.
Morgillo F; Sasso FC; Della Corte CM; Festino L; Manzo A; Martinelli E; Troiani T; Capuano A; Ciardiello F
Expert Opin Investig Drugs; 2013 Nov; 22(11):1401-9. PubMed ID: 23937224
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.
Lee JK; Hahn S; Kim DW; Suh KJ; Keam B; Kim TM; Lee SH; Heo DS
JAMA; 2014 Apr; 311(14):1430-7. PubMed ID: 24715074
[TBL] [Abstract][Full Text] [Related]
13. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.
Morgillo F; Sasso FC; Della Corte CM; Vitagliano D; D'Aiuto E; Troiani T; Martinelli E; De Vita F; Orditura M; De Palma R; Ciardiello F
Clin Cancer Res; 2013 Jul; 19(13):3508-19. PubMed ID: 23695170
[TBL] [Abstract][Full Text] [Related]
14. Integration of EGFR inhibitors and conventional chemotherapy in the treatment of non-small-cell lung cancer.
Pennell NA
Clin Lung Cancer; 2011 Nov; 12(6):350-9. PubMed ID: 21723791
[TBL] [Abstract][Full Text] [Related]
15. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
16. Anti-epidermal-growth-factor-receptor agents and complete responses in the treatment of advanced non-small-cell lung cancer: a meta-analysis of 17 phase III randomized controlled trials.
Qi WX; Fu S; Zhang Q; Guo XM
Curr Med Res Opin; 2015 Jan; 31(1):25-33. PubMed ID: 25329826
[TBL] [Abstract][Full Text] [Related]
17. Locally advanced NSCLC: current state of the art, treatment and future directions.
Choy H; Bonomi PD
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S23-30. PubMed ID: 19780243
[TBL] [Abstract][Full Text] [Related]
18. Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells.
Della Corte CM; Ciaramella V; Di Mauro C; Castellone MD; Papaccio F; Fasano M; Sasso FC; Martinelli E; Troiani T; De Vita F; Orditura M; Bianco R; Ciardiello F; Morgillo F
Oncotarget; 2016 Jan; 7(4):4265-78. PubMed ID: 26673006
[TBL] [Abstract][Full Text] [Related]
19. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor: A Meta-analysis of 25 RCTs.
Sheng Z; Zhang Y
Am J Clin Oncol; 2017 Aug; 40(4):362-369. PubMed ID: 25647830
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor tyrosine kinase inhibitors in previously treated advanced non-small-cell lung cancer with wild-type EGFR.
Mitsuoka S; Kawaguchi T; Kubo A; Isa S; Asai K; Uji M; Watanabe T; Sawa K; Yoshimoto N; Oka T; Nakai T; Suzumura T; Tanaka H; Matsuura K; Kimura T; Yoshimura N; Kudoh S; Hirata K
Expert Opin Pharmacother; 2016; 17(2):193-203. PubMed ID: 26781399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
